Publications scientifiques sur le VIH
Tesamorelin, a growth hormone-releasing factor analogue, improves inflammatory markers in HIV-infected patients with excess abdominal fat: relationships between changes in inflammatory markers and changes in visceral adipose tissue (VAT) [abstract].
2010
Antiviral Therapy
Mamputu J-C, Falutz J, Pham MH, et al.
15(suppl 4):A6. Proceedings of the 12th International Workshop on Adverse Drug Reactions and Co-Morbidities.
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
2010
J Acquir Immune Defic Syndr.
Falutz J, Potvin D, Mamputu J-C, et al.
53(3):311-322.
Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.
2009
Antimicrob Agents Chemother.
Jacobson JM, Kuritzkes DR, Godofsky E, et al.
53(2):450-457.
Pharmacokinetic/pharmacodynamic evaluation of tesamorelin (TH9507), a growth hormone releasing factor (GRF) analog, administered subcutaneously once daily for 14 consecutive days in healthy and HIV positive populations.
2009
Michaud S-E, Abolfathi Z, Potvin D, et al.
"Poster #P3-641 presented at: ENDO; June 10-13, 2009; Washington, DC, USA. "
Impact of tesamorelin (TH9507), a stabilized growth hormone-releasing factor (GRF) analogue, on the pharmacokinetics of simvastatin and ritonavir in healthy volunteers.
2009
Vincent G, Teng S, Ducharme MP, et al.
Poster #P178. Presented at: the 18th Annual Canadian Conference on HIV/AIDS Research (CAHR); April 24-27, 2009; Vancouver, British Columbia, Canada.